December 19, 2016 / 12:33 PM / 8 months ago

BRIEF-Concordia International Corp provides business update

Dec 19 (Reuters) - Concordia International Corp

* Decided to further reduce expenses by terminating its current contract sales team that was promoting donnatal

* Intends to redirect its resources to other potential pdt with photofrin opportunities

* Announced it will be removed from Nasdaq Biotech Index (nbi) effective prior to market opening on monday

* Paid first installment of its earn-out to Cinven relating to co's october 2015 acquisition of amdipharm mercury limited

* Believes that it has access to sufficient liquidity to meet all of its near term financial obligations

* Termination of company's phase 3 trial for photodynamic therapy with photofrin

* Concordia international corp provides business update Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below